CytomX Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

CTMX$1.980.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Income

CONDENSED STATEMENTS OF OPERA TIONS AND COMPREHENSIVE INCOME (LOSS)

(in thousands, except share and per share data)

Three Months Ended · Nine Months Ended
	September 30,		September 30,
	2026	2025	2026	2025
Revenues	$1,688	$5,963	$13,365	$75,538
Operating expenses:
Research and development	16,480	15,304	53,316	47,493
General and administrative	8,710	6,427	27,004	22,477
Total operating expenses	25,190	21,731	80,320	69,970
Income (loss) from operations	(23,502)	(15,768)	(66,955)	5,568
Interest income	3,271	1,592	7,918	3,725
Other income	294	5	305	33
Income (loss) before income taxes	(19,937)	(14,171)	(58,732)	9,326
Provision for income taxes	61	58	180	184
Net income (loss) attributable to common stockholders	(19,998)	(14,229)	(58,912)	9,142
Other comprehensive income (loss):
Unrealized gain (loss) on investments, net of tax	(119)	71	(426)	77
Total comprehensive income (loss)	$(20,117)	$(14,158)	$(59,338)	$9,219
Net income (loss) per share:
Basic	$(0.09)	$(0.09)	$(0.29)	$0.07
Diluted	$(0.09)	$(0.09)	$(0.29)	$0.07
Weighted average common shares used to compute net income (loss) per share
Basic	219,106,651	165,004,291	205,259,594	127,352,366
Diluted	219,106,651	165,004,291	205,259,594	128,859,852

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.